While HMA treatment alone still has very limited activity against AML, AZA has become indispensable as a combination partner for the BCL2-inhibitor venetoclax (VEN) or the IDH1 inhibitor ivosidenib (IVO, see below). Here, IDH1 is linked to acute myeloid leukemia.